Wednesday, March 14, 2012 7:35:00 PM
"On average, a business sale takes nine months to one year. "
My belief is that this process started when Fong stepped in.
"As you prepare to put your house on the market, you get the word out to as many people as possible. The "For Sale" sign is placed in the front yard, you invite people into your home during an open house and you put ads in the newspaper and online. You want everyone to know your house is for sale.
However, that's not the case when selling a business. Place an ad that your business is on the market and people start to wonder. It creates an air of uncertainty that can be detrimental to your bottom line and put the company in jeopardy.
To increase the likelihood of a successful sale of a business at an optimum price, keep it confidential!"
http://www.compass-advisors.com/index.php?content=keep-it-quiet-confidentiality-critical-to-business-sale
My belief is that this process started when Fong stepped in.
"As you prepare to put your house on the market, you get the word out to as many people as possible. The "For Sale" sign is placed in the front yard, you invite people into your home during an open house and you put ads in the newspaper and online. You want everyone to know your house is for sale.
However, that's not the case when selling a business. Place an ad that your business is on the market and people start to wonder. It creates an air of uncertainty that can be detrimental to your bottom line and put the company in jeopardy.
To increase the likelihood of a successful sale of a business at an optimum price, keep it confidential!"
http://www.compass-advisors.com/index.php?content=keep-it-quiet-confidentiality-critical-to-business-sale
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
